Regulatory Action Shuts Down Sipla's Medicine Distribution Hub in Wadki
In a decisive move, Maharashtra's FDA has terminated the operating licence of Sipla Pharma & Life Sciences Ltd's C&F warehouse situated in Wadki, Pune. The agency cited multiple alleged violations related to drug packaging, inventory control, storage conditions, and documentation practices.
The trigger for the enforcement was the packaging of Reactine Plus tablets, a Schedule‑H prescription medication. Authorities claimed the label made unapproved therapeutic claims, describing the product as a remedy for various aches, from headache to joint pain, and featured graphics of a human figure that suggested muscle‑pain relief.
Following directives from the Bombay High Court, the state drug controller revisited the case and, on October 1, signed an order cancelling the licence. The process began on August 27 when the FDA first moved against the warehouse, but the matter was later sent back for a revised procedural review.
Sipla was served a modified show‑cause notice on September 4, answered on September 11, and defended its position in a personal hearing on September 21. Upon evaluating the company’s response, supporting documents, and applicable statutes, the licensing authority concluded that the licence must be withdrawn, emphasizing that the decision rested on fresh evidence uncovered during the latest review.